Genomic and transcriptomic analyses of residual invasive triple-negative breast cancer after neoadjuvant chemotherapy in the prospective MIRINAE trial (a randomized phase II trial of adjuvant atezolizumab plus capecitabine compared to capecitabine; KCSG-BR18-21). - Im SA; Park K; Koh J; Park C; Jung KH; Lee J; Ahn HK; Lee A; Sim SH; Kim MH; Kim JH; Lee KE; et al. (ESMO open, 2025)